Spots Global Cancer Trial Database for neoplasms
Every month we try and update this database with for neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Hypopressive Exercise Associated With Strength and Resistance Training in Women Treated for Gynecological Cancer | NCT05493319 | Gynecologic Can... | Exercises | 18 Years - 60 Years | Universidade Federal de Sao Carlos | |
| A Registry Study of Breast Microseed Treatment | NCT02701244 | Breast Neoplasm... | Permanent Breas... | 50 Years - | Concure Oncology-Breast Microseed Inc. | |
| Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) | NCT03099031 | Venous Thromboe... | Tinzaparin | 18 Years - | LEO Pharma | |
| Exercise For Fighting Oncology Repercussions After Treatment | NCT05980325 | Neoplasms | Nordic Walking Aquatic Exercis... Functional Exer... | 18 Years - | Universitat Pompeu Fabra | |
| Biobehavioral Intervention in Gynecologic Oncology Patients | NCT02454036 | Neoplasms Ovarian Neoplas... Uterine Neoplas... Vulva | BBI interventio... | 21 Years - 80 Years | University of Kentucky | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling | NCT01868022 | Neoplasms | GSK3052230 paclitaxel carboplatin docetaxel pemetrexed cisplatin | 18 Years - | GlaxoSmithKline | |
| Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2 | NCT01837693 | Precancerous Co... Neoplasms | Experimental: i... | 25 Years - 59 Years | Azienda Unità Sanitaria Locale Reggio Emilia | |
| Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients | NCT01222728 | Neoplasms Nervous System ... Vestibular Dise... | 18 Years - 50 Years | National Institutes of Health Clinical Center (CC) | ||
| Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors | NCT03510104 | Advanced Cancer Metastatic Canc... Neoplasms Neoplasm Metast... Neoplastic Proc... Pathologic Proc... | MRX-2843 | 18 Years - | Meryx, Inc. | |
| Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer | NCT01538563 | Solid Tumors Advanced Cancer Cancer Neoplasms | rigosertib sodi... | 18 Years - | Traws Pharma, Inc. | |
| Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | NCT05964101 | Neoplasms Carcinoma, Squa... Antineoplastic ... | Nivolumab Injec... | 18 Years - 75 Years | The First Affiliated Hospital of Guangzhou Medical University | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | NCT04222972 | RET-fusion Non ... Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Disea... Head and Neck N... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Germ... Neoplasms, Nerv... | Pralsetinib Carboplatin Cisplatin Pemetrexed Pembrolizumab Gemcitabine Paclitaxel Nab-Paclitaxel | 18 Years - | Hoffmann-La Roche | |
| Trial Comparing Loop Ileostomy Versus Loop Transverse Colostomy | NCT05745909 | Rectal Neoplasm... Ostomy Neoplasms | Laparoscopic or... Laparoscopic or... | 18 Years - 79 Years | Republican Clinical Oncological Dispensary, Ministry of Health of the Republic of Bashkortostan | |
| Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer | NCT05386108 | Breast Neoplasm... Brain Neoplasms Neoplasms by Si... Neoplasms Breast Diseases Central Nervous... Brain Diseases Central Nervous... | Elacestrant Abemaciclib | 18 Years - | Stemline Therapeutics, Inc. | |
| The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy | NCT02192216 | Neoplasms | Exercise | 18 Years - | Department of Public Health, Denmark | |
| Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor | NCT00454649 | Neoplasms | Axitinib + Pacl... Axitinib + Pacl... Axitinib + Pacl... Axitinib + Pacl... Axitinib + Doce... Axitinib + Doce... Axitinib + Cape... Axitinib + Cape... Axitinib + Gemc... Axitinib + Peme... | 18 Years - | Pfizer | |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. | NCT00195325 | Tumors Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Research Study to Evaluate the Safety of R306465, a Drug in Development for Cancer and to Study the Absorption, Break Down and Elimination in Patients With Advanced Solid Malignancies. | NCT00677001 | Neoplasms | R306465 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study | NCT05149248 | Cancer of Cervi... | Gardasil® [Quad... Two dose Control group 2 dose vaccinat... | 14 Years - 45 Years | Instituto Nacional de Salud Publica, Mexico | |
| The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent | NCT01862198 | Bile Duct Obstr... Disorder of Bil... Neoplasms | EUS-guided bili... | 20 Years - | Inje University | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE) | NCT01304199 | Cancer | 18 Years - 75 Years | All India Institute of Medical Sciences, New Delhi | ||
| A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. | NCT00350090 | Anemia Neoplasms | Epoetin Alfa | 18 Years - | Ortho Biotech Products, L.P. | |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | NCT05874921 | Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Carc... Urothelial Canc... Urothelial Carc... Carcinoma, Tran... Transitional Ce... | Jelmyto (mitomy... | 18 Years - | UroGen Pharma Ltd. | |
| A Study of LY3022855 In Participants With Breast or Prostate Cancer | NCT02265536 | Neoplasms Neoplasm Metast... | LY3022855 | 18 Years - | Eli Lilly and Company | |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | NCT02984761 | Lung Neoplasm | Stereotactic Ra... Anatomic Pulmon... | 18 Years - | VA Office of Research and Development | |
| Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients | NCT03282643 | Neoplasms | Rivaroxaban 10 ... Rivaroxaban 20 ... Low-molecular-w... | 18 Years - 85 Years | Capital Medical University | |
| Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care | NCT02752061 | Neoplasms HIV Healthcare Disp... | Potlako interve... | 18 Years - | Harvard School of Public Health (HSPH) | |
| Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease | NCT04630743 | Dyspnea Respiratory Ins... Neoplasms Pulmonary Disea... Lung Diseases Heart Failure Lung Diseases, ... Palliative Care Palliative Medi... Breathlessness | Cognitive and B... | 18 Years - | University of Cologne | |
| RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL | NCT05902845 | Neoplasms Hematologic Neo... Hematologic Dis... | RD13-02 cell in... | 3 Years - 70 Years | Anhui Provincial Hospital | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Qigong for Breast Cancer Survivors | NCT02420249 | Neoplasms | Qigong training | 18 Years - | The University of Hong Kong | |
| An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers. | NCT02479061 | Neoplasms Oncology | 18 Years - | Centre Leon Berard | ||
| An Exploratory Study of the Use of Five Wishes as a Tool for Advanced Care Planning in Young Adults With Metastatic, Recurrent, or Progressive Cancer or HIV Infection | NCT01445145 | Neoplasms | 16 Years - 30 Years | National Institutes of Health Clinical Center (CC) | ||
| Cancer-associated Muscle Mass - Molecular Factors and Exercise Mechanisms | NCT05307367 | Cachexia Neoplasms Exercise Metabolism Body Compositio... Insulin Resista... Physical Functi... Quality of Life Sarcopenia Caregivers Adipose Tissue Muscle, Skeleta... Patient Reporte... Gastrointestina... Proteomics Lipidomics Epigenomics Mitochondria | Exercise traini... | 18 Years - 100 Years | University of Copenhagen | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| An Evaluation of the Fathers and Mothers With Cancer Communication Tool | NCT04342871 | Neoplasms Cancer Parenting Communication Parents Parent-Child Re... | Fam-CT | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours. | NCT00998296 | Neoplasms | BIBW 2992 BIBF 1120 | 18 Years - | Boehringer Ingelheim | |
| Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin | NCT00481936 | Neoplasms, Glan... | VB6-845 | 18 Years - | Sesen Bio, Inc. | |
| Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca | NCT01555489 | Stage IV Pancre... | Ascorbic Acid | 18 Years - | Thomas Jefferson University | |
| Study of Noni in Cancer Patients | NCT00033878 | Neoplasms Neoplasm Metast... | Noni Extract | - | National Center for Complementary and Integrative Health (NCCIH) | |
| A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | NCT04958239 | Neoplasms | BI 765179 Ezabenlimab | 18 Years - | Boehringer Ingelheim | |
| Real World Registry for Use of the Ion Endoluminal System | NCT06004440 | Lung Cancer Multiple Pulmon... Lung Neoplasms Respiratory Tra... Thoracic Neopla... Neoplasms by Si... Neoplasms Lung Diseases Respiratory Tra... | Ion Endoluminal... | 18 Years - | Intuitive Surgical | |
| Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism | NCT01164046 | Venous Thromboe... Neoplasms | low molecular w... vitamin K antag... | 18 Years - | University Medical Center Groningen | |
| Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma | NCT03168438 | Neoplasms | Letetresgene au... Letetresgene au... Fludarabine Cyclophosphamid... Pembrolizumab | 18 Years - | GlaxoSmithKline | |
| Methylnaltrexone for Opioid-induced Constipation in Cancer Patients | NCT01004393 | Neoplasms Constipation Opioid-Related ... | Methylnaltrexon... | 18 Years - | University of Vermont | |
| Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | NCT02269943 | Nasopharyngeal ... | CC-486 | 18 Years - | Celgene | |
| Open Label Study of BAY1082439 in Patients With Advanced Cancer | NCT01728311 | Neoplasms | BAY1082439 | 21 Years - | Bayer | |
| Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy | NCT05022667 | Thyroid Neoplas... Thyroid Disease... Hypoparathyroid... Endocrine Syste... Endocrine Gland... Neoplasms by Si... Neoplasms Head and Neck N... Parathyroid Dis... | PTeye | 18 Years - | University of Michigan | |
| Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers | NCT05834426 | Lymphoma, B-Cel... Neoplasms Cancer High-grade B-ce... Diffuse Large B... Non Hodgkin Lym... Metabolomics | Plasma metabolo... | 18 Years - | Sociedad de Lucha Contra el Cáncer del Ecuador | |
| A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | NCT02386111 | Carcinoma, Rena... Kidney Diseases Kidney Neoplasm... Urogenital Neop... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Hi... Clear-cell Meta... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers | NCT01523678 | Ovarian Cancer Endometrial Can... Uterine Cervica... | Filgrastim Paclitaxel Carboplatin | 18 Years - | Belgian Gynaecological Oncology Group | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | NCT01943851 | Neoplasms | GSK525762 | 18 Years - | GlaxoSmithKline | |
| A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia | NCT00117039 | Anemia Neoplasms | Aranesp® | 18 Years - | Amgen | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | NCT01540994 | Prostatic Neopl... | radiation thera... | 50 Years - 90 Years | Sharp HealthCare | |
| Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases | NCT05322486 | Colorectal Neop... Intestinal Neop... Gastrointestina... Digestive Syste... Neoplasms by Si... Neoplasms Neoplasms, Seco... Neoplasm Metast... Digestive Syste... Gastrointestina... Colonic Disease Intestinal Dise... Rectal Diseases | surgery of the ... chemotherapy | 18 Years - | State Scientific Centre of Coloproctology, Russian Federation | |
| A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test | NCT01649453 | Neoplasm Metast... | Pathwork® Tissu... | 18 Years - | Cedar Associates LLC | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | NCT03602157 | Lymphoma Immune System D... Immunoprolifera... Lymphatic Disea... Lymphoprolifera... Neoplasms Cutaneous Lymph... Cutaneous Anapl... Mycosis Fungoid... Sezary Syndrome Lymphomatoid Pa... Cutaneous T Cel... Gray Zone Lymph... | ATLCAR.CD30.CCR... ALTCAR.CD30 cel... Bendamustine Fludarabine | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | NCT02014116 | Neoplasms Neoplasm Metast... Melanoma Carcinoma, Non-... Colorectal Neop... | LY3009120 capsu... | 18 Years - | Eli Lilly and Company | |
| A Study of TY-1091 in Patients With Advanced Solid Tumors | NCT05675605 | RET-altered Non... Medullary Thyro... RET-altered Pap... Neoplasms | TY-1091 | 18 Years - 100 Years | TYK Medicines, Inc | |
| Exploring New Technologies to Manage Cancer Pain in the Community | NCT02341846 | Neoplasms Pain | Qualitative int... | 18 Years - | University of Aberdeen | |
| Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors | NCT02171637 | Neoplasms | BIBW 2992 | 18 Years - | Boehringer Ingelheim | |
| Study of AZD8931 in Patients With Advanced Solid Malignancies | NCT00637039 | Advanced Solid ... | AZD8931 | 18 Years - | AstraZeneca | |
| SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases | NCT03694015 | Neoplasm Metast... Neoplastic Proc... Neoplasms Pathologic Proc... | SUPR VMAT | 18 Years - | British Columbia Cancer Agency | |
| A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | NCT02309892 | Non-Small Cell ... | L-DOS47 | 18 Years - | Helix BioPharma Corporation | |
| Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial. | NCT06375850 | Phlebitis | Sesame oil Saline solution | 18 Years - | Hospital Universitario Marqués de Valdecilla | |
| Differential Expression of CD200 in B-chronic Lymphoproliferative Disorders by Multicolour Flow Cytometry | NCT03712488 | Neoplasms | flowcytometry | - | Assiut University | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread | NCT03166631 | Neoplasms Neoplasm Metast... Carcinoma, Non-... | BI 891065 BI 754091 | 18 Years - | Boehringer Ingelheim | |
| CAREgiver Study for Patients Undergoing HSCT | NCT03210727 | Neoplasms | Ready to CARE p... | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | NCT01235897 | Advanced Solid ... Tumors Cancer | MK-2206 Paclitaxel Trastuzumab | 18 Years - | University of California, San Francisco | |
| A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma | NCT02993731 | Carcinoma, Panc... | Napabucasin Nab-paclitaxel Gemcitabine | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors | NCT00264472 | Neoplasms | ADH300004 | 18 Years - | Adherex Technologies, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
